Chicago And Beerse

CHICAGO and BEERSE, Belgium, June 6, 2011 - - Data From DACO-016 Trial at 2011 American Society of Clinical Oncology Annual Meeting - NB: Data in this release corresponds to ASCO abstract 6504 Data from the DACO-016 trial of DACOGEN(R) (decitabine) presented today at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), demonstrate a clinically significant improvement in overall survival in older patients with newly diagnosed de novo or secondary acute myeloid leukemia (AML) as defined by the World Health Organisation (WHO).[1] AML is a life-threatening disease that affects primarily older adults; very limited treatment options exist.